Rituximab, an anti-CD20 antibody causing B-cell depletion in non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis, provides an additional candidate for T1DM treatment. The gene discussed is MS4A1; the disease is non-Hodgkin lymphoma.